Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Abiomed Inc., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
The analysis of the provided financial ratios reveals several noteworthy trends over the covered periods.
- Debt Ratios
- The debt to equity ratio exhibited stability in the periods from September 30, 2016, to September 30, 2017, maintaining values around 0.03 to 0.04. Specifically, it started at 0.04 in September 2016 and showed a minor decline to 0.03 by June 2017. This trend is mirrored by the debt to capital and debt to assets ratios, which also display slight decreases within the same timeframe, indicating a consistent but minimal reduction in relative debt levels during these quarters. There is no data available beyond September 2017 for these ratios, making further trend analysis impossible. However, the initial levels suggest a low reliance on debt financing.
- Financial Leverage
- The financial leverage ratio has been recorded continuously from June 30, 2016, through September 30, 2022. This ratio starts at 1.14 and shows a gradual increase to a peak of approximately 1.22 around March 31, 2017, which may imply a slight increase in the use of debt or other liabilities relative to equity during this period. From this peak onward, there is a steady and modest decline, reaching 1.10 by September 30, 2022. This downward trend in financial leverage suggests a gradual reduction in the company's relative financial risk or a potential strengthening of equity financing over time.
Overall, the data indicates that the company maintained low debt usage in the earlier periods recorded and slightly increased its financial leverage until early 2017, followed by a slow but consistent deleveraging trend. This pattern might reflect strategic decisions to strengthen the balance sheet or adjust the capital structure to a more conservative stance across time.
Debt Ratios
Debt to Equity
Abiomed Inc., debt to equity calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Current portion of capital lease obligation | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 851) | 829) | 799) | 770) | 740) | —) | ||||||||
| Capital lease obligation, net of current portion | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 15,110) | 15,325) | 15,539) | 15,750) | 15,961) | —) | ||||||||
| Total debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 15,961) | 16,154) | 16,338) | 16,520) | 16,701) | —) | ||||||||
| Stockholders’ equity | 1,539,787) | 1,536,196) | 1,503,326) | 1,432,938) | 1,384,563) | 1,307,522) | 1,329,675) | 1,261,441) | 1,182,409) | 1,101,848) | 1,065,466) | 1,046,863) | 991,457) | 1,002,593) | 936,890) | 851,530) | 792,954) | 723,359) | 689,524) | 632,482) | 604,886) | 567,044) | 452,071) | 417,380) | 398,441) | 377,327) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to equity1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.00 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.45 | 0.46 | 0.46 | 0.46 | 0.46 | 0.48 | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.66 | 0.68 | 0.66 | 0.66 | 0.66 | 0.65 | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.51 | 0.44 | 0.46 | 0.48 | 0.49 | 0.50 | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.80 | 0.87 | 0.74 | 0.65 | 0.71 | 0.65 | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 0 ÷ 1,539,787 = 0.00
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the periods presented. Total debt figures, available only for a limited set of quarters in 2016 and 2017, show a slight decrease from 16,701 thousand US dollars in September 2016 to 15,961 thousand US dollars in June 2017. This indicates a modest reduction in debt levels during this timeframe. However, due to the absence of data for subsequent periods, no further conclusions can be drawn regarding the company's leverage in later years.
Stockholders' equity exhibits a consistent and strong upward trend throughout the entire period from mid-2016 to late 2022. Starting at 377,327 thousand US dollars in June 2016, equity increases steadily to reach approximately 1,536,000 thousand US dollars by September 2022. This represents more than a fourfold increase over the six-year span, indicating significant growth in the company's net assets and a robust capital structure development.
The debt to equity ratio, available for only a few quarters in 2016 and early 2017, remains very low and stable between 0.03 and 0.04. This suggests that during this early period, the company maintained minimal leverage relative to its equity base. Due to the limited scope of this data, it is not possible to assess changes in leverage in the subsequent years.
Overall, the available data points to strong equity growth and a conservative approach to debt in the periods observed. The company appears to have built its equity base substantially, which may provide greater financial flexibility and an improved balance sheet position. The limited debt information restricts a comprehensive analysis of leverage trends over the entire timeline.
Debt to Capital
Abiomed Inc., debt to capital calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Current portion of capital lease obligation | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 851) | 829) | 799) | 770) | 740) | —) | ||||||||
| Capital lease obligation, net of current portion | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 15,110) | 15,325) | 15,539) | 15,750) | 15,961) | —) | ||||||||
| Total debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 15,961) | 16,154) | 16,338) | 16,520) | 16,701) | —) | ||||||||
| Stockholders’ equity | 1,539,787) | 1,536,196) | 1,503,326) | 1,432,938) | 1,384,563) | 1,307,522) | 1,329,675) | 1,261,441) | 1,182,409) | 1,101,848) | 1,065,466) | 1,046,863) | 991,457) | 1,002,593) | 936,890) | 851,530) | 792,954) | 723,359) | 689,524) | 632,482) | 604,886) | 567,044) | 452,071) | 417,380) | 398,441) | 377,327) | ||||||||
| Total capital | 1,539,787) | 1,536,196) | 1,503,326) | 1,432,938) | 1,384,563) | 1,307,522) | 1,329,675) | 1,261,441) | 1,182,409) | 1,101,848) | 1,065,466) | 1,046,863) | 991,457) | 1,002,593) | 936,890) | 851,530) | 792,954) | 723,359) | 689,524) | 632,482) | 620,847) | 583,198) | 468,409) | 433,900) | 415,142) | 377,327) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to capital1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.00 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.31 | 0.31 | 0.31 | 0.32 | 0.31 | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.40 | 0.41 | 0.40 | 0.40 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.34 | 0.31 | 0.31 | 0.32 | 0.33 | 0.34 | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.44 | 0.46 | 0.43 | 0.39 | 0.41 | 0.39 | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 0 ÷ 1,539,787 = 0.00
2 Click competitor name to see calculations.
The analysis of the financial data reveals distinct trends in the company's debt and capital structure over the periods presented.
- Total Debt
- The available data for total debt spans from September 30, 2016, to September 30, 2017. During this time, total debt exhibits a slight declining trend, decreasing from 16,701 thousand US dollars to 15,961 thousand US dollars. This steady reduction in debt suggests a conservative approach to leverage, possibly signaling efforts to improve financial stability or reduce interest expenses. No data is available beyond September 2017, limiting the assessment of debt behavior in later periods.
- Total Capital
- Total capital shows a consistent and significant upward trend from June 30, 2016, through September 30, 2022. Beginning at 377,327 thousand US dollars, capital increases steadily across all periods, reaching 1,539,787 thousand US dollars by the latest reporting date. This growth indicates sustained reinvestment and potential growth in equity financing or retained earnings. The steady rise in total capital reflects an expansion in the company's financial base and may also support increased operational capacity or strategic initiatives.
- Debt to Capital Ratio
- The debt to capital ratio is disclosed for periods between September 30, 2016, and September 30, 2017, where it remains low and stable, fluctuating slightly around 0.03 to 0.04. This low ratio signifies that debt constitutes a small portion of the total capital structure during these intervals, emphasizing a strong equity position and low financial risk from debt. The absence of subsequent data restricts the analysis of leverage trends in later periods.
Overall, the data indicates a company with a growing capital base and a minimal reliance on debt during the periods where data is available. The substantial increase in total capital over multiple years points to positive capital accumulation, while the decreasing and low debt levels suggest prudent financial management focused on maintaining low leverage. However, the incomplete data on debt and debt to capital ratios in later periods limits a comprehensive understanding of the company’s full financial leverage trajectory beyond 2017.
Debt to Assets
Abiomed Inc., debt to assets calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Current portion of capital lease obligation | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 851) | 829) | 799) | 770) | 740) | —) | ||||||||
| Capital lease obligation, net of current portion | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 15,110) | 15,325) | 15,539) | 15,750) | 15,961) | —) | ||||||||
| Total debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 15,961) | 16,154) | 16,338) | 16,520) | 16,701) | —) | ||||||||
| Total assets | 1,696,544) | 1,703,636) | 1,673,393) | 1,592,877) | 1,530,034) | 1,458,394) | 1,494,359) | 1,428,434) | 1,327,974) | 1,249,512) | 1,216,462) | 1,196,611) | 1,124,348) | 1,125,060) | 1,054,346) | 957,116) | 887,165) | 812,039) | 786,375) | 719,602) | 694,653) | 652,217) | 550,414) | 500,964) | 474,898) | 429,312) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to assets1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.00 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.29 | 0.26 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.23 | 0.25 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 0 ÷ 1,696,544 = 0.00
2 Click competitor name to see calculations.
The financial data reveals several trends regarding the company's debt and asset structure over the analyzed periods.
- Total Debt
- The available data for total debt spans from September 30, 2016, to September 30, 2017. During this timeframe, total debt demonstrated a gradual decline from 16,701 thousand US dollars in September 2016 to 15,961 thousand US dollars in September 2017. This gradual decrease suggests a modest reduction in outstanding obligations over these quarters.
- Total Assets
- Total assets increased consistently throughout the reported periods, starting from 429,312 thousand US dollars on June 30, 2016, and reaching 1,696,544 thousand US dollars by September 30, 2022. This upward trajectory indicates substantial growth and expansion of the company's asset base, with assets more than tripling over the six-year span. The increase appears steady without any notable contractions, highlighting sustained investments or asset acquisitions.
- Debt to Assets Ratio
- The debt to assets ratio, available from September 30, 2016, through June 30, 2017, remained low and showed a decline from 0.04 to 0.02 during this interval. This decreasing ratio reflects the reduction in total debt relative to the asset base, implying an improving financial leverage position and potentially a stronger balance sheet.
In summary, the data portrays a company that has been steadily growing its asset base over the periods in question while simultaneously reducing its debt levels slightly during the periods for which debt data is available. The resulting debt to assets ratio is very low and declining, suggesting conservative leverage and an improving financial stability profile as of mid-2017. Data beyond 2017 for total debt and the debt to assets ratio is not available, thus limiting full assessment of recent leverage trends. However, the consistent asset growth indicates continuing expansion efforts.
Financial Leverage
Abiomed Inc., financial leverage calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Total assets | 1,696,544) | 1,703,636) | 1,673,393) | 1,592,877) | 1,530,034) | 1,458,394) | 1,494,359) | 1,428,434) | 1,327,974) | 1,249,512) | 1,216,462) | 1,196,611) | 1,124,348) | 1,125,060) | 1,054,346) | 957,116) | 887,165) | 812,039) | 786,375) | 719,602) | 694,653) | 652,217) | 550,414) | 500,964) | 474,898) | 429,312) | ||||||||
| Stockholders’ equity | 1,539,787) | 1,536,196) | 1,503,326) | 1,432,938) | 1,384,563) | 1,307,522) | 1,329,675) | 1,261,441) | 1,182,409) | 1,101,848) | 1,065,466) | 1,046,863) | 991,457) | 1,002,593) | 936,890) | 851,530) | 792,954) | 723,359) | 689,524) | 632,482) | 604,886) | 567,044) | 452,071) | 417,380) | 398,441) | 377,327) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Financial leverage1 | 1.10 | 1.11 | 1.11 | 1.11 | 1.11 | 1.12 | 1.12 | 1.13 | 1.12 | 1.13 | 1.14 | 1.14 | 1.13 | 1.12 | 1.13 | 1.12 | 1.12 | 1.12 | 1.14 | 1.14 | 1.15 | 1.15 | 1.22 | 1.20 | 1.19 | 1.14 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 1.97 | 1.99 | 2.03 | 2.04 | 2.03 | 2.09 | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 2.86 | 2.92 | 2.83 | 2.86 | 2.82 | 2.79 | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 1.17 | 1.16 | 1.17 | 1.15 | 1.14 | 1.13 | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 1.80 | 1.71 | 1.73 | 1.75 | 1.76 | 1.78 | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 3.40 | 3.49 | 3.16 | 3.26 | 3.16 | 3.04 | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 1,696,544 ÷ 1,539,787 = 1.10
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several key trends in the reported items over the period from mid-2016 to late 2022.
- Total assets
-
Total assets demonstrate a consistent upward trajectory throughout the entire period. Starting at approximately 429 million US dollars in June 2016, total assets increased steadily to reach about 1.7 billion US dollars by September 2022. This growth reflects a significant expansion in the company's asset base, with no periods of notable decline or stagnation.
- Stockholders’ equity
-
Stockholders' equity similarly showed a positive and steady increase over time. Beginning near 377 million US dollars in June 2016, equity rose to approximately 1.54 billion US dollars by the latest quarter in September 2022. This rise parallels the growth in total assets, indicating retained earnings and capital accumulation. There is a minor fluctuation observed around late 2019, but the overall trend remains upward.
- Financial leverage
-
The financial leverage ratio started at 1.14 in June 2016 and fluctuated mildly throughout the periods, maintaining a narrow range between 1.10 and 1.22. There is a slight downward trend in leverage, moving from higher values around 1.22 in early 2017 toward lower values near 1.10 by the end of 2022. This suggests a moderate reduction in the reliance on debt financing relative to equity, signifying a strengthening of the equity base relative to total assets.
Overall, the data indicates sustained growth in both asset accumulation and equity financing, accompanied by a modest decrease in leverage. These patterns suggest improved financial stability and potentially enhanced capability for funding operations and expansion through shareholder equity rather than increased debt levels.